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Abstract
Background: Colorectal cancer (CRC) is one of the leading causes of malignant death worldwide.
Because young age of onset is often considered a poor prognostic factor for CRC, it is important to
identify the poor outcomes of CRC in a younger population and to consider an aggressive approach by
implementing early treatment. Our aim was to specifically quantify the fecal cytokeratin 19 (CK19)
transcript from CRC patients and investigate its correlation with clinical stage, tumor malignancy, and age.
Methods: The quantitation of fecal CK19 transcript was determined by a quantitative real-time reverse
transcription polymerase chain in 129 CRC patients (45 younger than 60 years at diagnosis) and 85 healthy
controls. The levels of CK19 protein were examined both in colonic cell lines and tissues.
Results: The analysis of 45 younger CRC patients (age  60 years) revealed that patients at the M1 stage
had significantly higher expression levels of fecal CK19 mRNA when compared with healthy controls (p <
0.001) and patients at the M0 stage (p = 0.004). Additionally, the degree of consistency between the mean
level of fecal CK19 mRNA and the distant metastatic rate in each age interval was up to 89% (p = 0.042).
Conclusion: These results indicate that high levels of fecal CK19 mRNA represent a potential marker for
colorectal malignancy and for aggressive treatment of younger CRC patients.
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Background
Colorectal cancer (CRC), which is a predominant gas-
trointestinal malignancy, is one of the most commonly
diagnosed tumors in both men and women, and is
becoming one of the major medical causes of economic
burden worldwide [1]. On average, the starting age of
CRC incidence begins at 40 years of age and rises sharply
at the age of 50-55 years [2]. Moreover, CRC is also the
second most common cause of cancer-related deaths
among men over 40 years of age [3].
Several clinicopathological features of CRC have been
studied to identify markers that could predict CRC out-
comes [4]. Numerous studies have shown that metastasis
through the blood or lymphatic vessels is a major compli-
cation of cancer, and affects the prognosis of patients with
primary carcinomas [5], therefore, methods developed to
detect disseminated tumor cells in the peripheral blood
and lymph nodes of patients have been evaluated. Many
genetic changes were found in metastatic tumors, and
some of them could be molecular markers for dissemi-
nated tumor cells [6]. CRC development and progression
were shown to be complex processes that are associated
with multiple genetic alterations [7]. One of these mutant
molecules, cytokeratin 19 (CK19), is differentially
expressed in the peripheral blood [8,9] and lymph nodes
[10] of patients with breast cancer, or in epithelial cells of
CRC patients with advanced Dukes' stage [11]. In addi-
tion, serum levels of the CK19 protein fragment CYFRA
21-1 were also evaluated in many cancers, and could rep-
resent a useful circulating tumor marker [12-14].
Because young age of onset is often considered a poor
prognostic factor for CRC [15,16], it is important to iden-
tify the poor outcomes of CRC in a younger population
and to consider an aggressive approach by implementing
early treatment [17], therefore, a potential marker that
allows the evaluation of colorectal malignancy in young
patients is necessary. In the search for CRC biomarkers,
many studies have suggested that a molecular test using
fecal material may allow the elucidation of the molecular
pathogenesis of CRC [18,19]. We previously reported that
the upregulation of CK19 in feces predicted the presence
of metastasis [20].
In the present study, we used quantitative real-time
reverse transcription polymerase chain reaction (qRT-
PCR) [21] to specifically quantify the CK19 transcript,
which is considered to be relatively specific for epithelial
cells in the feces of CRC patients. We also investigated the
correlation between fecal CK19 mRNA transcript levels
and clinical stage, tumor malignancy, and age.
Methods
Patients
One hundred twenty-nine CRC patients from Taipei Vet-
erans General Hospital and Cathay General Hospital pro-
vided informed consent to participate in this study, which
complied with the guidelines approved by the institu-
tional review boards. The mean age of the patients was 65
years (age range, 32-90 years) and the cohort included 79
males and 50 females. Their initial tumor stage and other
clinical characteristics were listed in Table 1. Abdominal
computed tomography (CT) was routinely performed to
monitor for the presence of metastasis; however, chest CT
was only performed in cases with suspected lung lesions.
Table 1: Characteristics of CRC patients and healthy controls
Factor Category CRC patients Healthy controls
Age (years) n 129 85
Mean (range) 65 (32-90) 57 (32-91)
Gender n 129 85
Male (%) 79 (61.2) 42 (49.4)
Female (%) 50 (38.8) 43 (50.6)
Tumor laction n 124
Right (%) 37 (29.8)
Left (%) 87 (70.2)
Tumor size (cm) n 123
Median (range) 4.2 (0.70-15.00)
Histologic differentiation n 121
Well/moderate (%) 108 (89.3)
Poor/undifferentiated (%) 13 (10.7)
Tumor depth n 128
T1+T2 (%) 33(25.8)
T3+T4 (%) 95(74.2)
Dukes' stage n 129
A+B+C (%) 103 (79.8)
D (%) 26 (20.2)BMC Cancer 2009, 9:376 http://www.biomedcentral.com/1471-2407/9/376
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Fecal samples and colonic tumor specimens
Solid fecal samples were collected from the 129 patients
prior to any surgical or chemical therapy, as described in
our previous report [20]. Briefly, approximately 0.5 g of
each fecal sample was preserved in 1 mL of guanidinium
thiocyanate buffer (10 mM Tris, pH 7.4; 200 mM NaCl; 1
mM EDTA, pH 8.0; 4 M guanidinium thiocyanate; 1% -
mercaptoethanol) at -80°C until needed. In addition,
fecal samples were collected from 85 healthy controls (age
range, 32-91 years; mean age, 57 years; 42 males and 43
females) (Table 1) who were examined by colonoscopy
and had no inflammatory bowel conditions. Colonic
tumor specimens from six CRC patients (patients 01-06;
age  60 years) were snap-frozen in liquid nitrogen imme-
diately after surgery. The tissues were then directly
homogenized for Western blot analysis, according to rou-
tine procedures.
Quantitation of fecal CK19 expression
Fecal total RNA and cDNA were obtained as described in
our previous reports [20,22]. Briefly, 1 g of fecal total
RNA was reverse transcribed using oligo(dT) primers
(One-Step RT-PCR kit;Bioman, Taiwan, ROC), according
to the manufacturer's instructions. The resulting cDNA
sample was used to perform quantitative PCR (qPCR).
Levels of fecal CK19 mRNA were measured using probes
from the Universal Probe Library and TaqMan Master Mix
in a LightCycler thermal cycler system, according to the
manufacturer's instructions (Roche Diagnostics GmbH,
Mannheim, Germany). The primers used to amplify CK19
(AF202321) were 5'-TTGTCCTGCAGATCGACAAC-3'
(forward) and 5'-GCCTGTTCCGTCTCAAACTT-3'
(reverse), which were used in combination with Universal
Probe #71. The primers for 18s rRNA (X03205) were 5'-
CTCAACACGGGAAACCTCAC-3' (forward) and 5'-CGC
TCCACCAACTAAGAACG-3' (reverse), which were used in
combination with Universal Probe #77. The LightCycler
software (version 4.05, Roche Diagnostics) was used to
analyze the qPCR kinetics and to calculate quantitative
data. Each run included a diluted (512-fold) cDNA from
HT-29 cells, which was used as a positive control to stand-
ardize the run-to-run differences in RNA quantity.
Immunodetection of CK19 protein in colonic cell lines and 
tissues
Four different-staged CRC cell lines (SW480: ATCC
number CCL-228; LS 174T: ATCC number CL-188; LoVo:
ATCC number CCL-229; HT-29: ATCC number HTB-38)
were cultured to harvest cellular protein. All cultured cells
were maintained in Dulbecco's Modified Eagle's Medium
with 5 mM glutamine, according to routine cell culture
procedures. The cellular lysate of each cell line was har-
vested by scraping off the cells in radioimmunoprecipita-
tion assay (RIPA) buffer (50 mM Tris-HCl (pH 7.4), 1 mM
EDTA, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholate, and proteinase inhibitors). Total protein
concentration was determined using the Bradford protein
assay kit (Bio-Rad Laboratories, Hercules, CA), according
to the manufacturer's instructions. For each sample, 5 g
of protein was mixed with reducing NuPAGE SDS sample
buffer (Life Technologies, Carlsbad, CA), denatured for 10
min at 95°C, separated by 15% SDS-PAGE, blotted onto
a polyvinylidene difluoride membrane (Millipore, Biller-
ica, MA), and probed with mouse anti-human CK19
(1:500; sc-6278; Santa Cruz Biotechnology, Santa Cruz,
CA) or rabbit anti-human Actin (1:500; sc-1616-R; Santa
Cruz Biotechnology), following standard procedures.
Blots were then incubated with anti-mouse (for CK19) or
anti-rabbit (for Actin) secondary antibodies (0.2 g/mL)
conjugated to horseradish peroxidase. All Western blots
were developed using the Western Blot Chemilumines-
cence Reagent (PerkinElmer Life and Analytical Sciences,
Waltham, MA), according to the manufacturer's instruc-
tions.
The two CRC cell lines LS 174T and LoVo were grown on
glass coverslips in a 24-well plate and were fixed with 4%
paraformaldehyde in PBS (1.37 mM NaCl, 2.7 mM KCl,
4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 8.3) and stained
for cellular CK19 using fluorescent immunocytochemis-
try. Fixed cells were blocked in PBS with 1.5% normal
horse serum (S-2000; Vector Laboratories, Burlingame,
CA) for 30 min at room temperature and were then
probed with mouse anti-human CK19 (1:100) antibody
for 16 h at 4°C:. Unbound primary antibody was
removed by two 5-min incubations with PBS, which were
followed by incubation with Cy3-conjugated goat anti-
mouse antibody (1:200; AP124C; Millipore) for 1 h at
room temperature. Cells were washed with PBS and DNA
was stained with 4',6' diamidino-2-phenylindole (DAPI).
The stained samples were then dehydrated, mounted, and
analyzed using a Nikon Eclipse 80i fluorescence micro-
scope (Nikon Instruments, Melville, NY).
To evaluate the expression of CK19 in colonic tissues,
Western blot analysis was performed using the protocol
described for the cell line experiment, with some modifi-
cations. Briefly, frozen CRC tissues were pulverized in
RIPA buffer using a tissue homogenizer and a sonicator.
The tissue lysates were then separated by SDS-PAGE and
immunoblotted as described above.
Statistical analysis
Data were statistically analyzed using the SPSS software
(SPSS, Chicago, IL). The Kruskal-Wallis test was applied to
assess the presence of significant differences in fecal CK19
expression across the groups of healthy controls and
patients without (M0 stage) and with (M1 stage) distant
metastasis. Two groups were compared using the Mann-
Whitney U test. A post hoc analysis was performed usingBMC Cancer 2009, 9:376 http://www.biomedcentral.com/1471-2407/9/376
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Dunn's multiple comparison for the significant Kruskal-
Wallis tests. The Pearson's correlation coefficient and a
percent matching statistic were assessed to correlate the
level of fecal CK19 expression with patient's clinicopatho-
logic features, or with the metastatic rates of patients in
different age intervals. Significance was set at p < 0.05.
Results
Age-related expression of fecal CK19 mRNA in patients 
with CRC
The median normalized level of fecal CK19 mRNA was
0.0073 (range, 0.0000-0.0665) in 85 healthy controls,
0.0146 (range, 0.0000-0.1528) in 129 CRC patients,
0.0142 (range, 0.0000-0.1183) in 103 patients without
distant metastasis (M0 stage), and 0.0159 (range, 0.0000-
0.1528) in 26 patients with distant metastasis (M1 stage).
In analyses of clinicopathologic features, the fecal CK19
expression was netatively correlated with patient's age (p
= 0.025), but positively correlated with tumor depth (p =
0.023). Other features including gender (p  = 0.578),
tumor location (p = 0.908), tumor size (p = 0.828), and
differentiation (p = 0.581) were not significantly corre-
lated with fecal CK19 expression. As shown in Figure 1,
mean values of fecal CK19 mRNA from patients and from
healthy controls, and the distant metastatic rate of
patients were depicted according to the age interval.
Among the 45 younger patients (age  60 years), patients
aged between 45 and 50 years (45  age < 50) had the
highest metastatic rate (27.3%, 3 of 11) in distant organs,
whereas no metastasis were found in the youngest patient
group (age  40 years). Additionally, the degree of consist-
ency between the mean level of fecal CK19 mRNA and the
distant metastatic rate was up to 89% (p  = 0.042) in
Correlations between the mean level of fecal CK19 mRNA and the distant metastatic rate for CRC patients Figure 1
Correlations between the mean level of fecal CK19 mRNA and the distant metastatic rate for CRC patients. 
Each mean level of fecal CK19 mRNA was calculated from patients (black square) or healthy controls (gray square) in the same 
age interval as indicated. A metastatic rate (black triangle) was calculated by the following formula: number of patient with M1 
stage/total number of patient in the same age interal ×100. Ages ranges of these subjects were 32--90 years for CRC patients 
and 32--91 years for healthy controls.
Table 2: Median levels of fecal CK19 mRNA from different age 
groups of CRC patients
Relative quantitation
M stage  60 years > 60 years p value
M0
n 36 67




Median 0.0313 0.0117 0.002
Range 0.0128-0.1528 0-0.0994BMC Cancer 2009, 9:376 http://www.biomedcentral.com/1471-2407/9/376
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younger age groups (age  60 years) and was low in older
age groups (age > 60 years) (-71%, p = 0.292). The mean
value profiles of fecal CK19 mRNA from patients and
healthy controls didn't show any consistency either in the
younger or older age groups.
As listed in Table 2, the younger patients with M1 stage (n
= 9) had significantly higher fecal CK19 expression levels
when compared with the older metastatic patients (n =
17), as assessed by the Mann-Whitney U test (p = 0.002).
This significant difference of fecal CK19 mRNA correlated
to the patients' ages was not found in the patients with M0
stage (p > 0.05). However, a significant difference was also
seen across these younger groups by the Kruskal-Wallis
test. (p = 0.004) The subsequent post hoc test in these
younger subjects revealed that patients with M1 stage (n =
9) had significantly higher expression of fecal CK19
mRNA when compared with healthy controls (n = 57) (p
< 0.001) or with patients with M0 stage (n = 36) (P =
0.004) (Figure 2). In contrast, no significantly different
levels of fecal CK19 expression were noted from groups of
older subjects (age > 60 years), such as patients with M0
(n = 67) and M1 stages, (n = 17) or healthy controls (n =
28) and patients with M1 stage.
Expression pattern of CK19 in various colonic cell lines
Based on the correlation observed between the levels of
CK19 expression and the age of the patient, we chose four
regular CRC cell lines (SW480, from a 50-year-old male;
LS 174T, from a 58-year-old female; LoVo, from a 56-year-
old male; HT-29, from a 44-year-old female) from donors
who were all under the age of 60 and determined their
endogenous levels of CK19 expression (40 KDa) using an
Relative expression of fecal CK19 from younger patients and  age-matched healthy controls Figure 2
Relative expression of fecal CK19 from younger 
patients and age-matched healthy controls. The levels 
of fecal CK19 were quantified by quantitative real-time PCR 
from who were under the age of 60, including 57 healthy 
controls, 36 patients with M0 stage, and 9 patients with M1 
stage. The relative expression of fecal CK19 mRNA was nor-
malized by dividing it by that for 18s rRNA for each fecal 
sample. A significant difference (p < 0.05) determined by 
Dunn's multiple comparison was directly indicated as p value. 
The horizontal lines represent the median values.
Western blot analysis of endogenous CK19 expression in  colonic cell lines Figure 3
Western blot analysis of endogenous CK19 expres-
sion in colonic cell lines. All CRC cell lines presented with 
heterotypic bands at 40 KDa (CK19) and ~37 KDa. Bands 
from two early-staged cells (SW480 and LS 174T) were 
weaker than those from two late-staged cells (LoVo and HT-
29). The molecular weight of Actin was 43 KDa. Antibodies, 
mouse anti-human CK19 antibody or rabbit anti-human 
Actin antibody.
Fluorescent immunocytochemistry of CK19 protein in CRC  cell lines Figure 4
Fluorescent immunocytochemistry of CK19 protein 
in CRC cell lines. A: the early-staged cell line, LS 174T cells 
(200 ×). B: the late-staged cell line, LoVo cells (200 ×). Both 
the cells were stained for cellular CK19 (a and d) with 
mouse anti-human CK19 antibody. Secondary antibody, Cy3-
conjugated goat anti-mouse antibody. b and e, nuclear stain 
(DAPI) of cells from a and d. c, merged image from a and b; 
f, merged image from d and e.BMC Cancer 2009, 9:376 http://www.biomedcentral.com/1471-2407/9/376
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immunoblot analysis (Figure 3). The two late-staged
(LoVo and HT-29) CRC cell lines produced more CK19
protein when compared with the two early-staged (SW48
and LS 174T) cells, under similar levels of Actin protein.
Moreover, one differentially expressed fragment (~37
KDa), which was smaller than the full-size CK19 protein,
was detected in all CRC cell lines but with differential
expressions. As shown in Figure 3, the expression level of
this smaller fragment increased in accordance with the
donor's clinical stage with the exception of that detected
in SW480 cells. Immunofluorescent staining using a spe-
cific anti-human CK19 antibody showed a dramatic
increase of CK19 protein in the cytosol of LoVo cells,
which is in accordance with the immunoblot findings
from the colon cell lines (Figure 4).
Immunoblotting of CK19 protein in clinical colonic tissues
The same CK19 antibody was used to determine if clinical
colonic tissues also exhibited altered levels of CK19 pro-
tein. As shown in Figure 5, colonic tumor specimens from
six younger patients expressed CK19 in a pattern that was
similar to that of the CRC cell lines (Figure 3) and was in
accordance with their clinical stages. Even though the lev-
els of CK19 protein (40 KDa) were not significantly differ-
ent among these tumor tissues, the smaller fragment (~37
KDa) was upregulated in the two patients with Dukes'
stage D (patient 05, a 52-year-old male; patient 06, a 49-
year-old female).
Discussion
Detection of CRC cells in feces using qRT-PCR may be
developed for clinical diagnosis [18]. Because of the
deregulation of apoptosis in CRC cells, cancer cells in
feces are thought to be more stable than other cells
sloughed from normal mucosa [23] and could even repre-
sent a target for the molecular diagnosis of CRC [24];
therefore, fecal molecules from exfoliated colonic cells are
currently being developed as potential markers for colonic
neoplasia [20].
We reported several fecal molecules that are differentially
expressed in CRC patients [21,22], and demonstrated that
CK19 expression in feces is possibly correlated with CRC
metastasis [20]. Moreover, CK19 has been used exten-
sively as a marker of micrometastasis and for the detection
of circulating tumor cells in many cancers [25]. Recent
studies showed that cancer patients with increased CK19
expression have lower survival rates [26]. In CRC patients,
the levels of CK19 expression in the blood are associated
with the presence of micrometastases [27,28].
In the present study, we determined that both tumor
depth and distant metastasis of CRC patients were signif-
icantly correlated with higher fecal CK19 expression lev-
els. The similar results were also reported by Wang et al. in
blood [29]; however, our data are more specific in CRC
because we using the samples directly from colonic tract
[18]. In addition, this significant difference was only
found in CRC patients aged less than 60 years of age.
Among these younger patients, we also found that the lev-
els of fecal CK19 mRNA varied according to the distant
metastatic rate in each age interval. In particular, CRC
patients aged between 45 and 50 years had both the high-
est mean value of fecal CK19 expression and distant met-
astatic rate, whereas the age-matched healthy controls had
maximum fecal CK19 expression between 55 and 60 years
of age. This means that the expression of fecal CK19
mRNA can be detected by qRT-PCR, and is significantly
correlated with distant metastasis in CRC patients
younger than 60 years. To our knowledge, very few reports
have discussed the correlation between the expression lev-
els of CK19 mRNA and the patient's age, especially in
CRC. Li et al. reported that CK19 expressed in normal
colon epithelial tissues is an aging-upregulated protein
[30] and Kim et al. demonstrated a higher positive rate of
fecal CK19 by immunodetection is found in gastrointesti-
nal cancer and inflammation [31]. Recently, Pontiggi et al.
suggested that cells expressing CK19 represent a subpopu-
lation of basal keratinocytes in neonates and young chil-
dren [32]. However, this is the first report that
demonstrates that the expression levels of CK19 mRNA in
feces of patients younger than 60 years may represent an
underlying colorectal malignancy because of the prior
exclusion of inflammatory bowel coditions. As reported
by Karsten et al. and Dozois et al., who found that young
people diagnosed with CRC are more likely to be in the
later stage of the disease [17,33], we also found that the
patients diagnosed with distant metastasis (9 of 45; 20%)
were younger than 60 years. If we setting the cut-off value
of 0.0142 (median value of patients with M0 stage), our
Western blot analysis of endogenous CK19 expression in  colonic tumor specimens Figure 5
Western blot analysis of endogenous CK19 expres-
sion in colonic tumor specimens. Six colonic tumor 
specimens from one patient (01) at Dukes' stage B, three 
(02-04) at stage C, and two (05 and 06) at sage D were all 
under the age of 60 years. Two of patients (patients 02 and 
03) presented with a monotypic band at 40 KDa (CK19) and 
others produced heterotypic bands at 40 KDa and ~37 KDa. 
The molecular weight of Actin was 43 KDa. Antibodies, 
mouse anti-human CK19 antibody or rabbit anti-human 
Actin antibody. P, HT-29 cells served as the positive control.BMC Cancer 2009, 9:376 http://www.biomedcentral.com/1471-2407/9/376
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data resulted in a high sensitivity 0.89 (95% CI, 0.79-
0.99) but a low specificity 0.47 (95% CI, 0.36-0.58) for
predicting young patients with M1 stage. This seems to
correspond to the purpose of molecular screening and
agree with Lemmon and Gardner who reported that a sig-
nature with high sensitivity but perhaps low specificity
may be preferred in the clinical laboratory [34]. Because of
the clinical significance of the association between fecal
CK19 expression and the age of the patients, we used four
CRC cell lines, and six colonic tumor tissues from young
donors for immunodetection of the CK19 protein. Our
immunoblot results revealed that the stage-related expres-
sion of CK19 was detected in certain young CRC cells.
Moreover, the expression difference in the two early-
staged cell lines, SW480 and LS 174T, was possibly caused
by a recurrence of the malignancy and metastasis in the
donor of SW480 cells later. These results suggest that
increased awareness should be promoted in young
patients who exhibit high expression levels of fecal CK19
mRNA, and that an aggressive CRC treatment should be
implemented for these patients. This upregulation of
CK19 was also observed LoVo cells when compared with
LS 174T cells, using immunofluorescent imaging.
Additionally, a smaller fragment was present in the CRC
cell lines and some colonic tissues, as assessed by immu-
noblot analysis. This result is in agreement with other
studies, which describe the presence of a similar two-frag-
ment pattern in immunoblots of CK19 [35]. We predicted
that the size of the smaller fragment was approximately 37
KDa. We suggest that this is possibly the CYFRA21-1 frag-
ment of CK19 because of the similar molecular weight
reported by Satoh et al. [36]. This fragment could be eval-
uated in blood to detect non-small cell lung cancer [37],
in saliva to detect oral squamous cell carcinoma [38], and
in urine to detect bladder cancer [39]. Although we can
not discriminate CYFRA 21-1 from CK19 via the qRT-PCR
in feces, the fecal CK19 can still partially reflect the
sloughed CRC cells because of a coincidence between the
data of feces and colonic tumor specimens (data not
shown). As reported for other types of cancer, the molec-
ular assessment of CK19 expression levels using mRNA
detection (qRT-PCR) was more sensitive, and was signifi-
cantly associated with poor disease prognosis [40]. Our
data are also consistent with the conclusions of Silva et al.
and Denis et al., who demonstrated that the analysis of
CK19 expression can be used to determine the presence of
micrometastatic cells, even if these authors performed
their assays in blood samples [27,28].
Conclusion
The identification of occult metastases by molecular
screening should improve the prediction of disease out-
comes for CRC patients [5,28]. In conclusion, our results,
together with those of others, indicate that high levels of
fecal CK19 mRNA represent a potential marker for color-
ectal malignancy in younger patients (age  60 years),
which implies that special awareness should be promoted
among younger patients with high levels of fecal CK19
mRNA, and that aggressive treatment should be imple-
mented for these patients. Additionally, the fecal CK19
molecule offers new insights into the study of the molec-
ular alterations of CRC through fecal analysis.
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